CAR T cell therapy for solid tumors is hampered by the availability of ideal targets, by the hostile tumor microenvironment that hinder tumor infiltration, suppress T cell activation and proliferation, and induce T cell exhaustion. 

Our research aims to address these different points for CAR T cell therapy of rhabdomyosarcoma and Wilms tumor.